Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.51 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | MLYCD | O95822 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | AGER | Q15109 | 2/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10349935 | 0.93 | MEN1 (0.56) | ADRA2CCXCR2ACHEKMT2AMEN1 | |
| SCHEMBL6176562 | 0.93 | CXCR2 (0.50) | ADRA2CCXCR2ACHEKMT2AMEN1 | |
| SCHEMBL698882 | 0.88 | ADRA2C (0.64) | ADRA2CKMT2AMEN1MLYCDHPGD | |
| SCHEMBL9716677 | 0.85 | ADRA2C (0.53) | ADRA2CKMT2AMEN1MAPTMLYCD | |
| SCHEMBL10660695 | 0.83 | BACE1 (0.52) | ADRA2CKMT2AMEN1MAPTMLYCD | |
| SCHEMBL6569544 | 0.83 | PKM (0.56) | ADRA2CKMT2AMEN1HPGDNPC1 | |
| SCHEMBL9716701 | 0.83 | ADRA2C (0.55) | ADRA2CKMT2AMEN1MAPTMLYCD | |
| SCHEMBL27601299 | 0.81 | SMN1; SMN2 (0.51) | ACHEKMT2AMEN1MAPTRECQL | |
| SCHEMBL10659082 | 0.80 | ADRA2C (0.48) | ADRA2CKMT2AMEN1MLYCDHPGD | |
| SCHEMBL6570858 | 0.80 | KDM4E (0.63) | ADRA2CACHEKMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949543-B2 | Amide derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-27 | — | — | US | disclosed |
| EP-1340750-B1 | AMIDE DERIVATIVES | YAMANOUCHI PHARMA CO LTD (JP) | 2005-08-17 | — | — | EP | disclosed |
| US-20040034232-A1 | Amide derivative | ASTELLAS PHARMA INC. (JP) | 2004-02-19 | — | — | US | disclosed |
| EP-1340750-A1 | AMIDE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-09-03 | — | — | EP | disclosed |
| US-6008235-A | Pyridyl substituted imidazoles | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-28 | — | — | US | disclosed |
| EP-0624159-B1 | PYRIDYL SUBSTITUTED IMIDAZOLES | SMITHKLINE BEECHAM CORP (US) | 1998-11-25 | — | — | EP | disclosed |
| US-5716972-A | Pyridyl substituted imidazoles | SMITHKLINE BEECHAM CORPORATION (US) | 1998-02-10 | — | — | US | disclosed |
| EP-0624159-A4 | PYRIDYL SUBSTITUTED IMIDAZOLES. | SMITHKLINE BEECHAM CORP (US) | 1995-04-12 | — | — | EP | disclosed |
| EP-0624159-A1 | PYRIDYL SUBSTITUTED IMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 1994-11-17 | — | — | EP | disclosed |
| WO-1993014082-A1 | PYRIDYL SUBSTITUTED IMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 1993-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034232-A1 | Amide derivative | HDAC2, ZC3HAV1, HDAC4 | ADRA2C 4531/4885CXCR2 1352/4885ACHE 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.